Date:2021.07.17	
Your Name:_Peiyuan Wang	
Manuscript Title:_ TP53 and CDKN2A mutations in patients with early-stage lung squamous cell carcinoma: an analy	sis
of the correlations and prognostic outcomes	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	article processing charges	the National Natural Science Foundation of China (Grant Number 82002497), and the Science and Technology Program of Fujian Province (Grant Number 2020J05072).
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
3	Royalties or licenses	_XNone	
4	Consulting fees	_XNone	

5	Payment or honoraria for	X None	
3	lectures, presentations,	_X_None	
	speakers bureaus,		
	manuscript writing or		
6	educational events Payment for expert	X None	
U	testimony		
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
7	Support for attending meetings and/or travel	_XNone	
8	Patents planned, issued or	_XNone	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	_XNone	
12	Descript of a mala manual	V. Name	
12	Receipt of equipment, materials, drugs, medical	_XNone	
	writing, gifts or other		
	services		
13	Other financial or non-	_XNone	
	financial interests		

The author reports funding support from the National Natural Science Foundation of China (Grant Number 82002497), and the Science and Technology Program of Fujian Province (Grant Number 2020J05072) for the article processing charges.

Please place an "X" next to the following statement to indicate your agreement:

Date:2021.07.17
Your Name:_ Feng Wang
Manuscript Title: <u>TP53 and CDKN2A mutations in patients with early-stage lung squamous cell carcinoma: an analysis</u>
of the correlations and prognostic outcomes
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	article processing charges	the National Natural Science Foundation of China (Grant Number 82002497), and the Science and Technology Program of Fujian Province (Grant Number 2020J05072).
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
3	Royalties or licenses	_XNone	
4	Consulting fees	_XNone	

5	Payment or honoraria for	X None	
3	lectures, presentations,	_XNone	
	speakers bureaus,		
	manuscript writing or		
6	educational events Payment for expert	X None	
U	testimony		
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
7	Support for attending meetings and/or travel	_XNone	
8	Patents planned, issued or	_XNone	
	pending		
9	Participation on a Data	X None	
3	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	_XNone	
12	D :	V N	
12	Receipt of equipment, materials, drugs, medical	_XNone	
	writing, gifts or other		
	services		
13	Other financial or non-	_XNone	
	financial interests		

The author reports funding support from the National Natural Science Foundation of China (Grant Number 82002497), and the Science and Technology Program of Fujian Province (Grant Number 2020J05072) for the article processing charges.

Please place an "X" next to the following statement to indicate your agreement:

Date:2021.07.17
Your Name:_ Hao He
Manuscript Title: TP53 and CDKN2A mutations in patients with early-stage lung squamous cell carcinoma: an analy
of the correlations and prognostic outcomes
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	article processing charges	the National Natural Science Foundation of China (Grant Number 82002497), and the Science and Technology Program of Fujian Province (Grant Number 2020J05072).
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
3	Royalties or licenses	_XNone	
4	Consulting fees	X None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_XNone	
6	Payment for expert testimony	_XNone	
7	Support for attending meetings and/or travel	_XNone	
8	Patents planned, issued or pending	_XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_XNone	
11	Stock or stock options	_XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_XNone	
13	Other financial or non- financial interests	_XNone	

The author reports funding support from the National Natural Science Foundation of China (Grant Number 82002497), and the Science and Technology Program of Fujian Province (Grant Number 2020J05072) for the article processing charges.

Please place an "X" next to the following statement to indicate your agreement:

Date:2021.07.17
Your Name:_ Yujie Chen
Manuscript Title: <u>TP53 and CDKN2A mutations in patients with early-stage lung squamous cell carcinoma: an analysis</u>
of the correlations and prognostic outcomes
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	article processing charges	the National Natural Science Foundation of China (Grant Number 82002497), and the Science and Technology Program of Fujian Province (Grant Number 2020J05072).
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
3	Royalties or licenses	_XNone	
4	Consulting fees	X None	

5	Payment or honoraria for	X None	
3	lectures, presentations,	_X_None	
	speakers bureaus,		
	manuscript writing or		
6	educational events Payment for expert	X None	
U	testimony		
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
7	Support for attending meetings and/or travel	_XNone	
8	Patents planned, issued or	_XNone	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	_XNone	
12	Descript of a mala manual	V. Name	
12	Receipt of equipment, materials, drugs, medical	_XNone	
	writing, gifts or other		
	services		
13	Other financial or non-	_XNone	
	financial interests		

The author reports funding support from the National Natural Science Foundation of China (Grant Number 82002497), and the Science and Technology Program of Fujian Province (Grant Number 2020J05072) for the article processing charges.

Please place an "X" next to the following statement to indicate your agreement:

Date:2021.07.17	
Your Name: Hui Lin	Manuscript
Title: TP53 and CDKN2A mutations in patients with early-stage lung squamous	cell carcinoma: an analysis of the
correlations and prognostic outcomes	
Manuscript number (if known):	
In the interest of transparency, we ask you to disclose all relationships/activities related to the content of your manuscript. "Related" means any relation with for parties whose interests may be affected by the content of the manuscript. Disclose to transparency and does not necessarily indicate a bias. If you are in doubt ab	or-profit or not-for-profit third losure represents a commitment

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	article processing charges	the National Natural Science Foundation of China (Grant Number 82002497), and the Science and Technology Program of Fujian Province (Grant Number 2020J05072).
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
3	Royalties or licenses	_XNone	
4	Consulting fees	_XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_XNone	
6	Payment for expert testimony	_XNone	
7	Support for attending meetings and/or travel	_XNone	
8	Patents planned, issued or pending	_XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_XNone	
11	Stock or stock options	_XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_XNone	
13	Other financial or non- financial interests	_XNone	

The author reports funding support from the National Natural Science Foundation of China (Grant Number 82002497), and the Science and Technology Program of Fujian Province (Grant Number 2020J05072) for the article processing charges.

Please place an "X" next to the following statement to indicate your agreement:

Date:2021.	.07.17
Your Name:_	Peng Chen
Manuscript T	Fitle: <u>TP53 and CDKN2A mutations in patients with early-stage lung squamous cell carcinoma: an analysi</u>
of the correla	ations and prognostic outcomes
Manuscript n	number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	article processing charges	the National Natural Science Foundation of China (Grant Number 82002497), and the Science and Technology Program of Fujian Province (Grant Number 2020J05072).
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
3	Royalties or licenses	_XNone	
4	Consulting fees	X None	

5	Payment or honoraria for	X None	
5	lectures, presentations,	_XNone	
	speakers bureaus,		
	manuscript writing or		
6	educational events Payment for expert	X None	
U	testimony		
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
7	Support for attending meetings and/or travel	_XNone	
8	Patents planned, issued or	_XNone	
	pending		
9	Participation on a Data	X None	
3	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	_XNone	
12	D :	V N	
12	Receipt of equipment, materials, drugs, medical	_XNone	
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	_XNone	

The author reports funding support from the National Natural Science Foundation of China (Grant Number 82002497), and the Science and Technology Program of Fujian Province (Grant Number 2020J05072) for the article processing charges.

Please place an "X" next to the following statement to indicate your agreement:

ate: <u>2021.07.17</u>
our Name:_ Xiaofeng Chen
Ianuscript Title:_TP53 and CDKN2A mutations in patients with early-stage lung squamous cell carcinoma: an analysis
f the correlations and prognostic outcomes
lanuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	article processing charges	the National Natural Science Foundation of China (Grant Number 82002497), and the Science and Technology Program of Fujian Province (Grant Number 2020J05072).
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
3	Royalties or licenses	_XNone	
4	Consulting fees	X None	

5	Payment or honoraria for	X None	
5	lectures, presentations,	_X_None	
	speakers bureaus,		
	manuscript writing or		
6	educational events Payment for expert	X None	
U	testimony		
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
7	Support for attending meetings and/or travel	_XNone	
8	Patents planned, issued or	_XNone	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	_XNone	
12	Descript of a mala manual	V. Name	
12	Receipt of equipment, materials, drugs, medical	_XNone	
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	_XNone	

The author reports funding support from the National Natural Science Foundation of China (Grant Number 82002497), and the Science and Technology Program of Fujian Province (Grant Number 2020J05072) for the article processing charges.

Please place an "X" next to the following statement to indicate your agreement:

Date:2021.07.17
Your Name:_ Shuoyan Liu
Manuscript Title:_ TP53 and CDKN2A mutations in patients with early-stage lung squamous cell carcinoma: an analysis
of the correlations and prognostic outcomes
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	article processing charges	the National Natural Science Foundation of China (Grant Number 82002497), and the Science and Technology Program of Fujian Province (Grant Number 2020J05072).
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
3	Royalties or licenses	_XNone	
4	Consulting fees	_XNone	

5	Payment or honoraria for	X None	
5	lectures, presentations,	_X_None	
	speakers bureaus,		
	manuscript writing or		
6	educational events Payment for expert	X None	
U	testimony		
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
7	Support for attending meetings and/or travel	_XNone	
8	Patents planned, issued or	_XNone	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	_XNone	
12	Descript of a mala manual	V. Name	
12	Receipt of equipment, materials, drugs, medical	_XNone	
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	_XNone	

The author reports funding support from the National Natural Science Foundation of China (Grant Number 82002497), and the Science and Technology Program of Fujian Province (Grant Number 2020J05072) for the article processing charges.

Please place an "X" next to the following statement to indicate your agreement: